新型人肠道来源LEAP2片段的鉴定与代谢特征分析
该研究对20例肥胖受试者RYGB术前术后小肠内分泌细胞进行全基因组表达分析,发现LEAP2表达上调,其分泌片段LEAP238-47在体外促胰岛素分泌,但在10名健康人中未观察到血糖调节效应。
要点
- RYGB术后小肠EEC中LEAP2表达上调
- LEAP238-47在体外促胰岛素分泌
- 健康人中未观察到血糖调节效应
核心结论
- RYGB术后小肠LEAP2表达上调,LEAP238-47在体外促胰岛素分泌,但在健康人中未显示血糖调节作用。
研究设计与样本
- 对20例肥胖受试者RYGB术前术后小肠EEC进行全基因组表达分析,并在健康人(n=10)中输注LEAP238-47。
主要发现
- RYGB持续增加LEAP2表达水平。
- LEAP238-47在体外人胰岛中刺激胰岛素释放,效果与GLP-1相当。
- LEAP238-47对GHSR活性有相互影响。
- 健康人输注LEAP238-47(n=10)在所选用剂量下与安慰剂相比无血糖调节效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The mechanisms underlying Roux-en-Y gastric bypass (RYGB) surgery-induced weight loss and the immediate postoperative beneficial metabolic effects associated with the operation remain uncertain. Enteroendocrine cell (EEC) secretory function has been proposed as a key factor in the marked metabolic benefits from RYGB surgery. OBJECTIVE: To identify novel gut-derived peptides with therapeutic potential in obesity and/or diabetes by profiling EEC-specific molecular changes in obese patients following RYGB-induced weight loss. SUBJECTS AND METHODS: Genome-wide expression analysis was performed in isolated human small intestinal EECs obtained from 20 gut-biopsied obese subjects before and after RYGB. Targets of interest were profiled for preclinical and clinical metabolic effects. RESULTS: Roux-en-Y gastric bypass consistently increased expression levels of the inverse ghrelin receptor agonist, liver-expressed antimicrobial peptide 2 (LEAP2). A secreted endogenous LEAP2 fragment (LEAP238-47) demonstrated robust insulinotropic properties, stimulating insulin release in human pancreatic islets comparable to the gut hormone glucagon-like peptide-1. LEAP238-47 showed reciprocal effects on growth hormone secretagogue receptor (GHSR) activity, suggesting that the insulinotropic action of the peptide may be directly linked to attenuation of tonic GHSR activity. The fragment was infused in healthy human individuals (n = 10), but no glucoregulatory effect was observed in the chosen dose as compared to placebo. CONCLUSIONS: Small intestinal LEAP2 expression was upregulated after RYGB. The corresponding circulating LEAP238-47 fragment demonstrated strong insulinotropic action in vitro but failed to elicit glucoregulatory effects in healthy human subjects.
引用
- Hagemann CA, Zhang C, Hansen HH, et al. Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. J Clin Endocrinol Metab. 2021. PMID: 33135737. doi:10.1210/clinem/dgaa803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。